Anna Cardus-Martinez

Avinguda Gran Via 199-203
Barcelona, CT 08908, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: July 23, 2025

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Journal: Clinical and translational medicine

Published: May 20, 2025

Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.

Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.

Journal: Cancers

Published: December 05, 2024

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Journal: International journal of molecular sciences

Published: September 17, 2024

Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies.

Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies.

Journal: Cancer research

Published: August 02, 2024

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Journal: Therapeutic advances in medical oncology

Published: July 13, 2024

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Journal: Head & neck

Published: April 08, 2024

Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center's decade of experience.

Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center's decade of experience.

Journal: Frontiers in oncology

Published: October 15, 2023

HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.

HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 03, 2023

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 07, 2023

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?

Journal: Pharmaceutics

Published: December 24, 2022

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis.

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis.

Journal: Frontiers in immunology

Published: November 30, 2022

Showing 1-12 of 58

Last Updated: 09/26/2026